Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
CNY 71.53
(1.26%)
CNY 71.53
(1.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -405.03 Million CNY | -38.95% |
| 2022 | -291.49 Million CNY | -12.01% |
| 2021 | -260.25 Million CNY | -46.01% |
| 2020 | -178.24 Million CNY | -22.26% |
| 2019 | -145.79 Million CNY | -94.23% |
| 2018 | -75.06 Million CNY | -1863.42% |
| 2017 | -3.82 Million CNY | 91.77% |
| 2016 | -46.44 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -647.85 Million CNY | -59.95% |
| 2024 Q2 | -274.7 Million CNY | 57.6% |
| 2024 Q3 | -328.8 Million CNY | -19.33% |
| 2023 Q4 | -405.03 Million CNY | 21.54% |
| 2023 Q3 | -516.19 Million CNY | -68.39% |
| 2023 Q1 | -511.77 Million CNY | -75.57% |
| 2023 FY | -405.03 Million CNY | -38.95% |
| 2023 Q2 | -306.55 Million CNY | 40.1% |
| 2022 Q2 | -382.05 Million CNY | 18.37% |
| 2022 Q1 | -468 Million CNY | -79.83% |
| 2022 Q3 | -325.76 Million CNY | 14.73% |
| 2022 FY | -291.49 Million CNY | -12.01% |
| 2022 Q4 | -291.49 Million CNY | 10.52% |
| 2021 Q1 | -256.65 Million CNY | -43.99% |
| 2021 Q2 | -310.34 Million CNY | -20.92% |
| 2021 Q4 | -260.25 Million CNY | 8.71% |
| 2021 Q3 | -285.08 Million CNY | 8.14% |
| 2021 FY | -260.25 Million CNY | -46.01% |
| 2020 Q4 | -178.24 Million CNY | 33.81% |
| 2020 Q1 | -335.41 Million CNY | -130.06% |
| 2020 FY | -178.24 Million CNY | -22.26% |
| 2020 Q3 | -269.28 Million CNY | 10.78% |
| 2020 Q2 | -301.83 Million CNY | 10.01% |
| 2019 Q3 | -104.63 Million CNY | -20.18% |
| 2019 FY | -145.79 Million CNY | -94.23% |
| 2019 Q4 | -145.79 Million CNY | -39.34% |
| 2019 Q1 | 145.06 Million CNY | 293.25% |
| 2019 Q2 | -87.06 Million CNY | -160.02% |
| 2018 FY | -75.06 Million CNY | -1863.42% |
| 2018 Q4 | -75.06 Million CNY | 0.0% |
| 2017 FY | -3.82 Million CNY | 91.77% |
| 2016 FY | -46.44 Million CNY | 0.0% |